Characterization of cells and mediators associated with pruritus in primary cutaneous T-cell lymphomas.
Cutaneous T-cell lymphoma
IL-31
Mast cells
Mycosis fungoides
Pruritus
Tryptase
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
28 Jul 2024
28 Jul 2024
Historique:
received:
04
04
2024
accepted:
14
06
2024
medline:
28
7
2024
pubmed:
28
7
2024
entrez:
28
7
2024
Statut:
epublish
Résumé
Patients with primary cutaneous T-cell lymphoma (CTCL) often experience severe and difficult-to-treat pruritus that negatively affects their quality of life (QoL). However, the mechanisms of pruritus in CTCL, including mycosis fungoides (MF), remain largely unknown, and detailed characteristics of CTCL-associated pruritus is not fully elucidated. To characterize pruritus in CTCL, cutaneous B-cell lymphoma (CBCL), and large plaque parapsoriasis (LPP), and to identify potential itch mediators involved in the pathogenesis of pruritus in CTCL patients. Clinical data and blood samples were collected from 129 healthy subjects and 142 patients. Itch intensity, QoL impairment, psychological distress, and sleep quality were assessed using validated questionnaires and instruments. Blood levels of BDNF, CCL24, GRP, IL-31, IL-33, sST2, substance P, TSLP, tryptase and total IgE were measured using ELISA or ImmunoCAP. Pruritus was prevalent in CTCL, LPP and CBCL patients, with higher prevalence and severity observed in CTCL. In CTCL, pruritus correlated with significant impairment in QoL, sleep, psychological distress. Compared to healthy controls, elevated levels of IL-31, IL-33, substance P, total IgE, tryptase, and TSLP were found in MF patients. A comparison of MF patients with and without pruritus revealed higher levels of IL-31, substance P, GRP, and CCL24 in the former. Itch intensity positively correlated with IL-31, GRP, CCL24, and tryptase levels. Pruritus significantly burdens CTCL patients, necessitating appropriate therapeutic management. Our findings suggest that various non-histaminergic mediators such as tryptase and IL-31 could be explored as novel therapeutic targets for managing pruritus in MF patients.
Identifiants
pubmed: 39068637
doi: 10.1007/s10238-024-01407-y
pii: 10.1007/s10238-024-01407-y
doi:
Substances chimiques
Interleukins
0
Cytokines
0
IL31 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
171Subventions
Organisme : This study was supported by intramural funding. Outside of it, Carolin Steinert was supported by Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) as part of a clinical research unit (CRU) 339 "food allergy and tolerance" - 428144812.
ID : 428144812
Informations de copyright
© 2024. The Author(s).
Références
Trautinger F, Eder J, Assaf C, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. Eur J Cancer. 2017;77:57–74. https://doi.org/10.1016/j.ejca.2017.02.027 .
doi: 10.1016/j.ejca.2017.02.027
pubmed: 28365528
Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO–EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703–14. https://doi.org/10.1182/blood-2018-11-881268 .
doi: 10.1182/blood-2018-11-881268
pubmed: 30635287
pmcid: 6473500
Ottevanger R, van Beugen S, Evers AWM, et al. Quality of life in patients with Mycosis Fungoides and Sézary Syndrome: a systematic review of the literature. J Eur Acad Dermatol Venereol. 2021;35(12):2377–87. https://doi.org/10.1111/jdv.17570 .
doi: 10.1111/jdv.17570
pubmed: 34331819
pmcid: 9291074
Raap U, Ständer S, Metz M. Pathophysiology of itch and new treatments. Curr Opin Allergy Clin Immunol. 2011;11(5):420–7. https://doi.org/10.1097/ACI.0b013e32834a41c2 .
doi: 10.1097/ACI.0b013e32834a41c2
pubmed: 21772138
Misery L, Pierre O, Le Gall-Ianotto C, et al. Basic mechanisms of itch. J Allergy Clin Immunol. 2023;152(1):11–23. https://doi.org/10.1016/j.jaci.2023.05.004 .
doi: 10.1016/j.jaci.2023.05.004
pubmed: 37201903
Hashimoto T, Yosipovitch G. Itching as a systemic disease. J Allergy Clin Immunol. 2019;144(2):375–80. https://doi.org/10.1016/j.jaci.2019.04.005 .
doi: 10.1016/j.jaci.2019.04.005
pubmed: 31004615
Sutaria N, Adawi W, Goldberg R, et al. Itch: pathogenesis and treatment. J Am Acad Dermatol. 2022;86(1):17–34. https://doi.org/10.1016/j.jaad.2021.07.078 .
doi: 10.1016/j.jaad.2021.07.078
pubmed: 34648873
Biazus Soares G, Guitart J, Yosipovitch G. What’s new in cutaneous T-Cell lymphoma-associated pruritus. Am J Clin Dermatol. 2024;25:67–77. https://doi.org/10.1007/s40257-023-00823-2 .
doi: 10.1007/s40257-023-00823-2
pubmed: 37971624
Hu M, Scheffel J, Elieh-Ali-Komi D, et al. An update on mechanisms of pruritus and their potential treatment in primary cutaneous T-cell lymphoma. Clin Exp Med. 2023;23(8):4177–97. https://doi.org/10.1007/s10238-023-01141-x .
doi: 10.1007/s10238-023-01141-x
pubmed: 37555911
pmcid: 10725374
Kempf W, Mitteldorf C. Cutaneous T-cell lymphomas-An update 2021. Hematol Oncol. 2021;39(Suppl 1):46–51. https://doi.org/10.1002/hon.2850 .
doi: 10.1002/hon.2850
pubmed: 34105822
Bergerot CD, Philip EJ, Bergerot PG, et al. Discrepancies between genitourinary cancer patients’ and clinicians’ characterization of the Eastern Cooperative Oncology Group performance status. Cancer. 2021;127(3):354–8. https://doi.org/10.1002/cncr.33238 .
doi: 10.1002/cncr.33238
pubmed: 33007114
Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713–22. https://doi.org/10.1182/blood-2007-03-055749 .
doi: 10.1182/blood-2007-03-055749
pubmed: 17540844
Krause K, Kessler B, Weller K, et al. German version of ItchyQoL: validation and initial clinical findings. Acta Derm Venereol. 2013;93(5):562–8. https://doi.org/10.2340/00015555-1544 .
doi: 10.2340/00015555-1544
pubmed: 23494363
Desai NS, Poindexter GB, Monthrope YM, et al. A pilot quality-of-life instrument for pruritus. J Am Acad Dermatol. 2008;59(2):234–44. https://doi.org/10.1016/j.jaad.2008.04.006 .
doi: 10.1016/j.jaad.2008.04.006
pubmed: 18550210
Burns A, Höfer S, Curry P, Sexton E, Doyle F. Revisiting the dimensionality of the Hospital Anxiety and Depression Scale in an international sample of patients with ischaemic heart disease. J Psychosom Res. 2014;77(2):116–21. https://doi.org/10.1016/j.jpsychores.2014.05.005 .
doi: 10.1016/j.jpsychores.2014.05.005
pubmed: 25077852
Gandek B, Ware JE, Aaronson NK, et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998;51(11):1171–8. https://doi.org/10.1016/s0895-4356(98)00109-7 .
doi: 10.1016/s0895-4356(98)00109-7
pubmed: 9817135
Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213. https://doi.org/10.1016/0165-1781(89)90047-4 .
doi: 10.1016/0165-1781(89)90047-4
pubmed: 2748771
Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76. https://doi.org/10.1093/jnci/85.5.365 .
doi: 10.1093/jnci/85.5.365
pubmed: 8433390
Hawro T, Przybyłowicz K, Spindler M, et al. The characteristics and impact of pruritus in adult dermatology patients: A prospective, cross-sectional study. J Am Acad Dermatol. 2021;84(3):691–700. https://doi.org/10.1016/j.jaad.2020.08.035 .
doi: 10.1016/j.jaad.2020.08.035
pubmed: 32798581
Spindler M, Przybyłowicz K, Hawro M, et al. Sleep disturbance in adult dermatologic patients: A cross-sectional study on prevalence, burden, and associated factors. J Am Acad Dermatol. 2021;85(4):910–22. https://doi.org/10.1016/j.jaad.2021.04.015 .
doi: 10.1016/j.jaad.2021.04.015
pubmed: 33864837
Lewis DJ, Huang S, Duvic M. Inflammatory cytokines and peripheral mediators in the pathophysiology of pruritus in cutaneous T-cell lymphoma. J Eur Acad Dermatol Venereol. 2018;32(10):1652–6. https://doi.org/10.1111/jdv.15075 .
doi: 10.1111/jdv.15075
pubmed: 29775497
Demierre MF, Gan S, Jones J, Miller DR. Significant impact of cutaneous T-cell lymphoma on patients’ quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey. Cancer. 2006;107(10):2504–11. https://doi.org/10.1002/cncr.22252 .
doi: 10.1002/cncr.22252
pubmed: 17048251
Vij A, Duvic M. Prevalence and severity of pruritus in cutaneous T cell lymphoma. Int J Dermatol. 2012;51(8):930–4. https://doi.org/10.1111/j.1365-4632.2011.05188.x .
doi: 10.1111/j.1365-4632.2011.05188.x
pubmed: 22788808
Olszewska-Szopa M, Sobas M, Laribi K, et al. Primary cutaneous indolent B-cell lymphomas—a retrospective multicenter analysis and a review of literature. Acta Oncol. 2021;60(10):1361–8. https://doi.org/10.1080/0284186x.2021.1956689 .
doi: 10.1080/0284186x.2021.1956689
pubmed: 34346830
Chairatchaneeboon M, Thanomkitti K, Kim EJ. Parapsoriasis-A diagnosis with an Identity crisis: a narrative review. Dermatol Ther (Heidelb). 2022;12(5):1091–102. https://doi.org/10.1007/s13555-022-00716-y .
doi: 10.1007/s13555-022-00716-y
pubmed: 35426607
Ottevanger R, van Beugen S, Evers AWM, et al. Itch in patients with cutaneous T-cell lymphoma as a quality of life indicator. JAAD Int. 2022;9:57–64. https://doi.org/10.1016/j.jdin.2022.07.007 .
doi: 10.1016/j.jdin.2022.07.007
pubmed: 36147217
pmcid: 9486110
Sahin E, Hawro M, Weller K, et al. Prevalence and factors associated with sleep disturbance in adult patients with psoriasis. J Eur Acad Dermatol Venereol. 2022;36(5):688–97. https://doi.org/10.1111/jdv.17917 .
doi: 10.1111/jdv.17917
pubmed: 35020226
Pereira MP, Farcas A, Zeidler C, Ständer S. Chronic pruritus of unknown origin: clinical profile and disease-related burden. Acta Derm Venereol. 2021;101(9):adv00550. https://doi.org/10.2340/00015555-3892 .
doi: 10.2340/00015555-3892
pubmed: 34405244
Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340–7. https://doi.org/10.1016/j.anai.2018.07.006 .
doi: 10.1016/j.anai.2018.07.006
pubmed: 30025911
Beuers U, Wolters F, Oude Elferink RPJ. Mechanisms of pruritus in cholestasis: understanding and treating the itch. Nat Rev Gastroenterol Hepatol. 2023;20(1):26–36. https://doi.org/10.1038/s41575-022-00687-7 .
doi: 10.1038/s41575-022-00687-7
pubmed: 36307649
Sanders KM, Akiyama T. The vicious cycle of itch and anxiety. Neurosci Biobehav Rev. 2018;87:17–26. https://doi.org/10.1016/j.neubiorev.2018.01.009 .
doi: 10.1016/j.neubiorev.2018.01.009
pubmed: 29374516
pmcid: 5845794
Siiskonen H, Harvima I. Mast cells and sensory nerves contribute to neurogenic inflammation and pruritus in chronic skin inflammation. Front Cell Neurosci. 2019;13:422. https://doi.org/10.3389/fncel.2019.00422 .
doi: 10.3389/fncel.2019.00422
pubmed: 31619965
pmcid: 6759746
Thangam EB, Jemima EA, Singh H, et al. The role of histamine and histamine receptors in mast cell-mediated allergy and inflammation: the hunt for new therapeutic targets. Front Immunol. 2018;9:1873. https://doi.org/10.3389/fimmu.2018.01873 .
doi: 10.3389/fimmu.2018.01873
pubmed: 30150993
pmcid: 6099187
Rabenhorst A, Schlaak M, Heukamp LC, et al. Mast cells play a protumorigenic role in primary cutaneous lymphoma. Blood. 2012;120(10):2042–54. https://doi.org/10.1182/blood-2012-03-415638 .
doi: 10.1182/blood-2012-03-415638
pubmed: 22837530
Kolkhir P, Elieh-Ali-Komi D, Metz M, Siebenhaar F, Maurer M. Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases. Nat Rev Immunol. 2022;22(5):294–308. https://doi.org/10.1038/s41577-021-00622-y .
doi: 10.1038/s41577-021-00622-y
pubmed: 34611316
Solinski HJ, Kriegbaum MC, Tseng PY, et al. Nppb neurons are sensors of mast cell-induced itch. Cell Rep. 2019;26(13):3561-3573.e3564. https://doi.org/10.1016/j.celrep.2019.02.089 .
doi: 10.1016/j.celrep.2019.02.089
pubmed: 30917312
pmcid: 6490177
Collington SJ, Westwick J, Williams TJ, Weller CL. The function of CCR3 on mouse bone marrow-derived mast cells in vitro. Immunology. 2010;129(1):115–24. https://doi.org/10.1111/j.1365-2567.2009.03151.x .
doi: 10.1111/j.1365-2567.2009.03151.x
pubmed: 20050333
pmcid: 2807492
Menzies-Gow A, Ying S, Sabroe I, et al. Eotaxin (CCL11) and eotaxin-2 (CCL24) induce recruitment of eosinophils, basophils, neutrophils, and macrophages as well as features of early- and late-phase allergic reactions following cutaneous injection in human atopic and nonatopic volunteers. J Immunol. 2002;169(5):2712–8. https://doi.org/10.4049/jimmunol.169.5.2712 .
doi: 10.4049/jimmunol.169.5.2712
pubmed: 12193745
Hashimoto T, Rosen JD, Sanders KM, Yosipovitch G. Possible roles of basophils in chronic itch. Exp Dermatol. 2019;28(12):1373–9. https://doi.org/10.1111/exd.13705 .
doi: 10.1111/exd.13705
pubmed: 29894005
Wang F, Trier AM, Li F, et al. A basophil-neuronal axis promotes itch. Cell. 2021;184(2):422-440.e417. https://doi.org/10.1016/j.cell.2020.12.033 .
doi: 10.1016/j.cell.2020.12.033
pubmed: 33450207
pmcid: 7878015
Shimizu K, Andoh T, Makino T, et al. Mechanisms of itching in mycosis fungoides: grade of itching correlates with eosinophil infiltration and kallikrein 5 expression. Eur J Dermatol. 2019;29(3):268–73. https://doi.org/10.1684/ejd.2019.3560 .
doi: 10.1684/ejd.2019.3560
pubmed: 31389785
Nakashima C, Ishida Y, Kitoh A, Otsuka A, Kabashima K. Interaction of peripheral nerves and mast cells, eosinophils, and basophils in the development of pruritus. Exp Dermatol. 2019;28(12):1405–11. https://doi.org/10.1111/exd.14014 .
doi: 10.1111/exd.14014
pubmed: 31365150
Altrichter S, Frischbutter S, Fok JS, et al. The role of eosinophils in chronic spontaneous urticaria. J Allergy Clin Immunol. 2020;145(6):1510–6. https://doi.org/10.1016/j.jaci.2020.03.005 .
doi: 10.1016/j.jaci.2020.03.005
pubmed: 32224275
Kühn H, Kolkhir P, Babina M, et al. Mas-related G protein-coupled receptor X2 and its activators in dermatologic allergies. J Allergy Clin Immunol. 2021;147(2):456–69. https://doi.org/10.1016/j.jaci.2020.08.027 .
doi: 10.1016/j.jaci.2020.08.027
pubmed: 33071069
Kural YB, Su O, Onsun N, Uras AR. Atopy, IgE and eosinophilic cationic protein concentration, specific IgE positivity, eosinophil count in cutaneous T Cell lymphoma. Int J Dermatol. 2010;49(4):390–5. https://doi.org/10.1111/j.1365-4632.2010.04228.x .
doi: 10.1111/j.1365-4632.2010.04228.x
pubmed: 20465692
Roy S, Chompunud Na Ayudhya C, Thapaliya M, Deepak V, Ali H. Multifaceted MRGPRX2: new insight into the role of mast cells in health and disease. J Allergy Clin Immunol. 2021;148(2):293–308. https://doi.org/10.1016/j.jaci.2021.03.049 .
doi: 10.1016/j.jaci.2021.03.049
pubmed: 33957166
pmcid: 8355064
Hu M, Pyatilova P, Altrichter S, et al. In the skin lesions of patients with mycosis fungoides, the number of MRGPRX2-expressing cells is increased and correlates with mast cell numbers. Front Immunol. 2023;14:1197821. https://doi.org/10.3389/fimmu.2023.1197821 .
doi: 10.3389/fimmu.2023.1197821
pubmed: 38022672
pmcid: 10646224
Meixiong J, Anderson M, Limjunyawong N, et al. Activation of mast-cell-expressed mas-related G-protein-coupled receptors drives non-histaminergic Itch. Immunity. 2019;50(5):1163-1171.e1165. https://doi.org/10.1016/j.immuni.2019.03.013 .
doi: 10.1016/j.immuni.2019.03.013
pubmed: 31027996
pmcid: 6531358
Wang Z, Babina M. MRGPRX2 signals its importance in cutaneous mast cell biology: Does MRGPRX2 connect mast cells and atopic dermatitis? Exp Dermatol. 2020;29(11):1104–11. https://doi.org/10.1111/exd.14182 .
doi: 10.1111/exd.14182
pubmed: 32866307
Roth N, Städler S, Lemann M, et al. Distinct eosinophil cytokine expression patterns in skin diseases—the possible existence of functionally different eosinophil subpopulations. Allergy. 2011;66(11):1477–86. https://doi.org/10.1111/j.1398-9995.2011.02694.x .
doi: 10.1111/j.1398-9995.2011.02694.x
pubmed: 21884530
Provost V, Larose MC, Langlois A, et al. CCL26/eotaxin-3 is more effective to induce the migration of eosinophils of asthmatics than CCL11/eotaxin-1 and CCL24/eotaxin-2. J Leukoc Biol. 2013;94(2):213–22. https://doi.org/10.1189/jlb.0212074 .
doi: 10.1189/jlb.0212074
pubmed: 23532518
Tancrède-Bohin E, Ionescu MA, de La Salmonière P, et al. Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas. Arch Dermatol. 2004;140(9):1057–61. https://doi.org/10.1001/archderm.140.9.1057 .
doi: 10.1001/archderm.140.9.1057
pubmed: 15381544
Kabashima K, Irie H. Interleukin-31 as a Clinical Target for Pruritus Treatment. Front Med (Lausanne). 2021;8:638325. https://doi.org/10.3389/fmed.2021.638325 .
doi: 10.3389/fmed.2021.638325
pubmed: 33644103
Bağci IS, Ruzicka T. IL-31: A new key player in dermatology and beyond. J Allergy Clin Immunol. 2018;141(3):858–66. https://doi.org/10.1016/j.jaci.2017.10.045 .
doi: 10.1016/j.jaci.2017.10.045
pubmed: 29366565
Kunsleben N, Rüdrich U, Gehring M, et al. IL-31 Induces chemotaxis, calcium mobilization, release of reactive oxygen species, and CCL26 in eosinophils, Which are capable to release IL-31. J Invest Dermatol. 2015;135(7):1908–11. https://doi.org/10.1038/jid.2015.106 .
doi: 10.1038/jid.2015.106
pubmed: 25789701
Dillon SR, Sprecher C, Hammond A, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004;5(7):752–60. https://doi.org/10.1038/ni1084 .
doi: 10.1038/ni1084
pubmed: 15184896
Singer EM, Shin DB, Nattkemper LA, et al. IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus. J Invest Dermatol. 2013;133(12):2783–5. https://doi.org/10.1038/jid.2013.227 .
doi: 10.1038/jid.2013.227
pubmed: 23698099
Nattkemper LA, Martinez-Escala ME, Gelman AB, et al. Cutaneous T-cell lymphoma and pruritus: the expression of IL-31 and its receptors in the skin. Acta Derm Venereol. 2016;96(7):894–8. https://doi.org/10.2340/00015555-2417 .
doi: 10.2340/00015555-2417
pubmed: 27001482
Cedeno-Laurent F, Singer EM, Wysocka M, et al. Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. Clin Immunol. 2015;158(1):1–7. https://doi.org/10.1016/j.clim.2015.02.014 .
doi: 10.1016/j.clim.2015.02.014
pubmed: 25762519
pmcid: 4420663